A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Intravenous Infusion and Subcutaneous Administration of TAK-079 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs TAK 079 (Primary) ; TAK 079 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Takeda
- 04 Dec 2018 Results assessing safety of TAK-079 in healthy subjects, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 20 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History